bioRxivBiochemistryPreprint
Targeted protein degradation in lysosome utilizing naturally produced bifunctional antibodies with high levels of mannose 6-phosphate glycans
Andrew C. HedmaniD, Shou Liu, Jennifer Srnak, Riley N. Marcinczyk, Stephanie Do, Linda Lyons, Stuart Kornfeld, Hung DoiD, Lin LiuiD
Abstract
Novel antibodies have been created for targeted degradation of extracellular and membrane proteins in the lysosome. The mechanism of degradation of target proteins for these antibodies has involved either chemical conjugation of synthetic mannose 6-phosphate (M6P) or engineered bispecific antibodies. Currently, recombinant antibodies cannot be produced with naturally phosphorylated N-glycans. Here, we report the development of a novel platform technology for producing bifunctional therapeutic antibodies with high levels of M6P-bearing glycans directly from producing cells. The antibodies designated as phosphorylated N-glycosylated peptide chimeric antibodies (PNCA) maintain their affinity for antigens with concurrent high affinity binding to cell surface cation-independent mannose-6-phosphate receptors that facilitate internalization and delivery of antibody/antigen complexes to lysosomes for efficient degradation of both target extracellular soluble and membrane proteins. This PNCA approach provides a simple, scalable, and viable approach for producing naturally phosphorylated bifunctional antibodies from production cell lines for targeted protein degradation in lysosomes.
- assay: protein structure
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: protein folding & dynamics
- research focus: cell type annotation
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Bispecific antibody targeting of lipid nanoparticles
Angelo Amabile, Matthew Phelan, … Brian D. Brown·bioRxiv·Dec 20, 2024
- Selection of nanobodies against liponanoparticle-embedded membrane proteins by yeast surface display
Greg J. Dodge, Hayley L. Knox, … Karen N. Allen·Protein SciencePeer-reviewed·Sep 13, 2025
- Multivalent Ligand-Protein Interactions Using Polymeric Lysosome-Targeting Chimeras (PolyTACs) Leads to Lysosome-Targeting Receptor-Independent Degradation of Transmembrane Proteins
Ranit Dutta, Yasin Alp, … S. Thayumanavan·bioRxiv·May 6, 2025
- Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell-surface markers
Bettina Dietmair, James Humphries, … Seth W. Cheetham·Molecular Therapy — Nucleic AcidsPeer-reviewed·Mar 19, 2025
- A Versatile Antibody Capture System that Drives Precise In Vivo Delivery of mRNA loaded Lipid Nanoparticles and Enhances Gene Expression
Moore Z. Chen, Daniel Yuen, … Angus P. R. Johnston·Nature NanotechnologyPeer-reviewed·Aug 4, 2025
- Intracellular delivery of full-length antibodies via organ targeted lipid nanoparticles
Azmain Alamgir, Militsa Yaneva, … Christopher A. Alabi·Proceedings of the National Academy of SciencesPeer-reviewed·Jun 23, 2026